WO2009084662A1 - 哺乳動物体細胞用培地及びそのための添加剤 - Google Patents
哺乳動物体細胞用培地及びそのための添加剤 Download PDFInfo
- Publication number
- WO2009084662A1 WO2009084662A1 PCT/JP2008/073806 JP2008073806W WO2009084662A1 WO 2009084662 A1 WO2009084662 A1 WO 2009084662A1 JP 2008073806 W JP2008073806 W JP 2008073806W WO 2009084662 A1 WO2009084662 A1 WO 2009084662A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medium
- cells
- ligand
- serum
- growth factor
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/825—Serotonine (5-HT); Melatonine
Definitions
- the present invention relates to a medium used when culturing mammalian somatic cells outside the body and an additive for constituting the medium.
- Serum is usually blood derived from an individual from which the somatic cell to be cultured is derived, for example, autologous serum obtained from the blood of a patient from whom the somatic cell to be cultured is collected, or heterologous serum such as bovine serum. Used.
- any serum are not completely elucidated, and the components may vary depending on the origin of the serum used and the lot of commercially available products. In this case, there is a problem that it is difficult to make the quality of the cultured cells obtained constant.
- somatic cells in a medium that does not use serum or suppresses the amount used.
- Patent Document 1 JP-T-11-506610 discloses a serum-free medium for human mesenchymal cells containing a minimum essential medium, serum albumin, iron source, insulin and glutamine. It is described that serotonin having mitogenic activity of human mesenchymal cells may be added to this serum-free medium. However, even when mesenchymal stem cells are cultured in a serum-free medium supplemented with serotonin, there is a problem that the growth is relatively slow, and the cell characteristics change in a short period of time, resulting in a decrease in proliferation.
- JP-T-2006-505248 includes a lysophospholipid receptor, that is, a ligand of an endothelial cell differentiation gene (Edg) family receptor, such as lysophosphatidic acid (LPA), sphingosine monophosphate (S1P), etc. Serum-free media for regulating human embryonic stem (ES) cell differentiation has been disclosed. LPA is also known to have an effect of suppressing the differentiation of preadipocytes into adipocytes (J. Biol. Chem. Vol. 280, 15, 656 14656-14662 (2005); Non-Patent Document 1). LPA is also known to have a cell growth promoting effect (Sci.SSTKE, Vol.
- Non-Patent Document 3 American Journal of Respiratory Cell and Molecular Biology. Vol. 34, pp. 274-285, 2006; Non-Patent Document 3
- the cell growth promoting effect was confirmed in a serum-containing medium, and cell growth in a serum-free medium or a low serum medium of 1% or less The promoting effect is not known.
- Patent Document 3 describes a serum-free medium for human bone marrow-derived mesenchymal stem cells.
- ITS additives insulin, transferrin, selenium-containing additives
- bFGF basic fibroblast growth factor
- HGF hepatocyte growth factor
- TGF- ⁇ transforming growth factor
- PDGF platelet-derived growth factor
- cytokines and growth factors affect the proliferation of pluripotent cells in mammals including humans.
- PDGF platelet-derived growth factor
- bFGF basic fibroblast growth factor
- EGF epithelial cell growth factor
- PDGF platelet-derived growth factor
- bFGF basic fibroblast growth factor
- EGF epithelial cell growth factor
- N-acetyl-L-cysteine has the effect of reducing cell death by inhibiting apoptosis when culturing mammalian somatic cells including humans in vitro (Molecular Human Reproduction). Vol.8, No3.3, pp. 228-236, 2002; Non-Patent Document 8, J Leukoc Biol. Vol.76, No.1, pp. 152-61, 2004;
- the present invention suppresses the addition of serum to the medium as much as possible or can effectively proliferate mammalian somatic cells without adding serum. It is an object to provide a culture medium and an additive for constituting the culture medium.
- the inventors of the present invention have found that the medium contains no or only a small amount of serum by adding a ligand for the endothelial cell differentiation gene (Edg) family receptor and a ligand for the serotonin receptor to the medium.
- Edg endothelial cell differentiation gene
- the present invention provides a medium for mammalian somatic cells comprising a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor.
- the present invention also provides an additive for a medium for mammalian somatic cells containing a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor.
- the culture medium and the culture medium additive of the present invention can efficiently proliferate somatic cells under conditions where the serum conventionally added to the culture medium is not used or the amount of addition is reduced. enable. Therefore, problems that have occurred due to the use of serum, that is, burden on patients, contamination of infectious pathogens, and the like can be solved. Further, even when serum is added, it is possible to suppress the variation in cell proliferation caused by the variation between lots of serum to be added. Furthermore, even if human serum is used as serum, somatic cells can be efficiently proliferated. In addition, since the somatic cells can be cultured while suppressing the amount of serum used, the cultured cells of stable quality can be provided by the culture method of the present invention. Therefore, the obtained cultured somatic cells can be stable quality cultured somatic cells in which the problem of contamination with infectious pathogens is minimized.
- “somatic cells” are cells other than germ cells among the cells constituting multicellular organisms, and there are several types of differentiated cells that do not become other cells specialized for a certain purpose. And cells capable of differentiating into cells having different functions.
- the former cells are adult functional cells, and include cells that form organs in the body such as skin cells, nerve cells, muscle cells, blood cells, fibroblasts, liver cells, chondrocytes, and fat cells. .
- the latter is called a stem cell, and is a cell that can be transdifferentiated into at least one kind of differentiated cells among the differentiated cells, and includes embryonic stem cells and somatic stem cells.
- Somatic stem cells are cells excluding embryonic stem cells among stem cells and progenitor cells that have the ability to differentiate into cells having several different functions, and are induced multifunctional stem cells, hematopoietic stem cells, mesenchymal cells Includes stem cells, neural stem cells, skin stem cells, liver stem cells, pancreatic stem cells, and the like.
- the cells cultured in the medium of the present invention are not limited as long as they are mammalian somatic cells.
- Preferred examples include mesenchymal cells such as fibroblasts, adipose tissue-derived stem cells, and bone marrow-derived mesenchymal cells.
- somatic stem cells such as stem cells, but are not limited thereto.
- the medium of the present invention contains a ligand for the endothelial cell differentiation gene (Edg) family receptor as an essential component.
- the Edg family receptors are a group of G protein-coupled receptors with high homology in their gene sequences.
- Edg-1 to Edg-8 have been identified in mammals such as humans, mice, and sheep.
- Non-Patent Documents 4 and 5 Of these, Edg-2, Edg-4 and Edg-7 function as LPA receptors, and Edg-1, Edg-3, Edg-5, Edg-6 and Edg-8 are known to function as S1P receptors. It has been.
- a “ligand for a receptor” is a substance that specifically binds to the receptor, and includes not only natural ligands existing in the body, but also other natural or synthesized compounds known as agonists and antagonists. Include.
- the ligand for the Edg family receptor includes lysophosphatidic acid (LPA) and salts thereof, sphingosine monophosphate (S1P), and an agonist of the Edg family receptor.
- LPA lysophosphatidic acid
- S1P sphingosine monophosphate
- One or more compounds selected from the above are preferred.
- An agonist of an Edg family receptor is a substance that binds to an Edg family receptor and acts similarly to LPA and S1P.
- dihydrosphingosine monophosphate platelet activating factor (PAF), sphingosylphosphorylcholine, alkyl LPA analog, FTY720 etc. are mentioned.
- LPA is the following general formula (I): R—O—CH 2 CH (OH) CH 2 PO 4 H 2 (I) (Wherein R is an alkyl group having 10 to 30 carbon atoms, an alkenyl group having 10 to 30 carbon atoms, or an acyl group having 10 to 30 carbon atoms) It is a compound represented by these.
- the carbon number of the acyl group for the R group of the above formula (I) does not include the carbon number of the carbonyl group.
- the salt of LPA a conventionally known salt can be used, and examples thereof include alkali metal salts such as sodium salt and potassium salt, ammonium salt and the like.
- Examples of the salt of LPA or LPA include 1-oleoyl lysophosphatidic acid sodium salt and LPA potassium salt.
- the medium of the present invention further contains a ligand for serotonin receptors (hereinafter sometimes referred to as “serotonin ligand” for convenience).
- Serotonin receptors are a type of G protein-coupled receptor mainly found in the central nervous system.
- the serotonin ligand is preferably one or more compounds selected from serotonin, salts thereof and serotonin agonists. Serotonin is also called 5-hydroxytryptamine and is known to act as a neurotransmitter.
- a serotonin agonist is a substance known to bind to a serotonin receptor and act similarly to serotonin.
- PADD 1- [2- (4-aminophenyl) ethyl] -4- (3-bifluoromethylphenyl) piperazine
- DP-5CT N-dipropyl-5-carboxyamidotryptamine
- HT ⁇ -methyl-5-hydroxytryptamine
- 2-methyl-5-HT etc.
- the salt of serotonin a conventionally known salt can be used, and examples thereof include hydrochloride.
- the medium of the present invention preferably further contains an antioxidant.
- Preferred examples of the antioxidant include at least one selected from the group consisting of N-acetylcysteine (NAC), L-cysteine, catalase, superoxide dismutase and 2-mercaptoethanol, more preferably N-acetylcysteine and There may be mentioned at least one selected from the group consisting of L-cysteine.
- NAC N-acetylcysteine
- L-cysteine catalase
- L-cysteine There may be mentioned at least one selected from the group consisting of L-cysteine.
- These antioxidants are known to have an apoptosis-inhibiting action and are therefore effective for maintaining and growing cultured cells.
- Antioxidants can be used alone or in combination of two or more.
- the concentration of the antioxidant in the medium is preferably 0.01 mM to 10 mM, more preferably 0.1 mM to 1 mM.
- the concentration of albumin in the medium (the total concentration when multiple types are included) is preferably 0.0001 to 10% by weight, more preferably 0.0001 to 1% by weight.
- the medium of the present invention preferably further contains a growth factor.
- a growth factor By containing a growth factor, the proliferation of cultured cells is further promoted.
- growth factors include epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial cells
- growth factor VEGF
- G-CSF granulocyte colony stimulating factor
- GM-CSF granulocyte macrophage colony stimulating factor
- EPO erythropoietin
- TPO thrombopoietin
- HGF hepatocyte growth factor
- the medium of the present invention may further contain a ligand (PDGF) for platelet-derived growth factor receptor (PDGFR), and in particular, a medium for culturing mesenchymal stem cells preferably contains this.
- PDGFR is a kind of tyrosine kinase-related receptor that is mainly present in mesenchymal cells. By containing a ligand for PDGFR, it is possible to efficiently proliferate mesenchymal stem cells.
- PDGFR ligands include PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD, all of which are well known. PDGFR ligands can be used alone or in combination of two or more.
- the medium of the present invention may contain a ligand (FGF) for basic fibroblast growth factor receptor (FGFR), and in particular, a medium for culturing mesenchymal stem cells preferably contains this.
- FGF ligand
- FGFR is known to exist mainly in mesenchymal cells, and by including a ligand for this, the life span of mesenchymal stem cells is improved.
- ligands for PDGFR it is known that there are a total of 20 or more types such as basic fibroblast growth factor (bFGF) and acidic fibroblast growth factor (aFGF). Examples thereof include FGF-1 and FGF-4.
- bFGF is known to be strongly involved in tissue formation. These are all well known.
- the concentration of growth factor (the total concentration when multiple types are included) is preferably 0.1 to 100 ng / mL, more preferably 1 to 10 ng / mL.
- the medium of the present invention may further contain a surfactant. It is considered that the inclusion of a low concentration of the surfactant has an effect of reducing adverse effects on the cell membrane. On the other hand, it is known that when a high concentration surfactant is added to a medium, cell growth inhibition or cell death is induced.
- Surfactants include polyoxyethylene sorbitan fatty acid esters (trade names Tween 20, Tween 40, Tween 60, Tween 80, etc.), alkylphenoxy polyethylene glycols (trade name, Triton X-100, etc.), alkyl phenyl polyethylene glycols (trade names)
- Nonionic surfactants such as Triton® X-114 and NP-40 are preferred. Surfactants can be used alone or in combination of two or more.
- the medium of the present invention may contain serum in the same manner as a normal mammalian cell medium.
- the medium of the present invention contains both Edg ligand and serotonin ligand, so that the medium does not contain serum or contains only a low concentration. Even if it exists, since a cell can be efficiently proliferated, when the culture medium is a serum-free culture medium or a low serum culture medium, the power of this invention is exhibited most. That is, the serum content in the medium of the present invention is preferably 0 to 5% by weight, more preferably 0 to 1% by weight, based on the total amount of the medium. In the present specification and claims, a medium containing serum but containing 5% by weight or less, preferably 1% by weight is called a low serum medium.
- the medium of the present invention is a known mammalian cell except that it contains one or more of the above-mentioned Edg ligand and serotonin ligand, preferably, the above-mentioned antioxidant, animal serum albumin, growth factor and surfactant. It may be the same as the culture medium. Therefore, basically, by adding one or more of the above-mentioned two essential components, preferably one of the above preferred components, to a known basal medium, preferably serum-free or low serum basal medium, A medium can be obtained.
- a known basal medium preferably serum-free or low serum basal medium
- serum-free basal media include minimal essential medium (MEM) such as Eagle medium, Dulbecco's modified Eagle medium (DMEM), minimum essential medium ⁇ (MEM- ⁇ ), mesenchymal cell basal medium (MSCBM), Ham's F-12 and F-10 medium, DMEM / F12 medium, Williams medium E, RPMI-1640 medium, MCDB medium, 199 medium, Fisher medium, Iscove modified Dulbecco medium (IMDM), McCoy modified medium, etc. .
- MEM minimal essential medium
- DMEM Dulbecco's modified Eagle medium
- MSCBM mesenchymal cell basal medium
- DMEM / F12 medium Williams medium E
- RPMI-1640 medium RPMI-1640 medium
- MCDB medium 199 medium
- Fisher medium Iscove modified Dulbecco medium
- McCoy modified medium McCoy modified medium, etc.
- the medium of the present invention may further contain various additives that are well known to be included in mammalian cell culture media.
- additives include amino acids, inorganic salts, vitamins, and other additives such as carbon sources and antibiotics.
- Amino acids include glycine, L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-glutamine, L-histidine, L-isoleucine, L- Mention may be made of leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine.
- vitamin B1 As vitamins, choline, vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B4, vitamin B5, vitamin B6, vitamin B7, vitamin B12, vitamin B13, vitamin B15, vitamin B17, vitamin Bh, vitamin Bt, vitamin Mention may be made of Bx, vitamin C, vitamin D, vitamin E, vitamin F, vitamin K, vitamin M and vitamin P.
- the amount of each additive may be the same as that of a known medium, and can be appropriately set by a routine test.
- the addition amount of amino acids is usually about 5 mg / L to 500 mg / L, preferably about 10 mg / L to 400 mg / L for each amino acid
- the addition amount of inorganic salts is usually about each inorganic salt.
- 0 mg / L to 10 mg / L preferably about 0.01 mg / L to 7 mg / L
- the amount of vitamins added is about 0.01 mg / L to 500 mg / L for each vitamin.
- it is about 0.05 mg / L to 300 mg / L.
- additives include (1) growth factors such as corticosterone and progesterone, (2) antibiotics such as penicillin, streptomycin, gentamicin and kanamycin, (3) carbon sources such as glucose, galactose, fructose and sucrose, (4) Trace metals such as magnesium, iron, zinc, calcium, potassium, sodium, copper, selenium, cobalt, tin, molybdenum, nickel and silicon, and adenosine 5'-monophosphate, corticosterone, ethanolamine, insulin
- Other additives such as reduced glutathione, lipoic acid, hypoxanthine, phenol red, progesterone, putrescine, pyruvate, thymidine, triiodothyronine, transferrin and lactoferrin.
- the addition amount of these additives may be the same as the conventional one, and can be appropriately set by a routine test according to the purpose of each additive. Usually, it is about 0.001 to 5 mg
- the medium of the present invention can be used for culturing for the growth or maintenance of somatic cells, and can also be used for inducing differentiation of stem cells when the cells to be cultured are stem cells.
- a differentiation inducer is further added.
- Differentiation inducers include cytokines (various interleukins, erythropoietin, thrombopoietin, etc.), colony stimulating factors (eg, G-CSF), steroid hormones (eg, dexamethasone), indoles (eg, indomethacin), thiazolidine derivatives (eg, rosiglitazone) Etc.
- cytokines variant interleukins, erythropoietin, thrombopoietin, etc.
- colony stimulating factors eg, G-CSF
- steroid hormones eg, dexamethasone
- indoles eg, indomethacin
- the medium of the present invention can contain one or more of the various additives described above, and usually contains a combination of a plurality of additives.
- Culture of mammalian somatic cells in the medium of the present invention can be carried out in the same manner as in the prior art, and is usually performed at a temperature of 30 to 37 ° C., in a 5% CO 2 environment, and 5 to 21% O. Performed in two environments.
- the present invention also provides an additive for constituting the above-described culture medium of the present invention. Therefore, the additive of the present invention contains the above-mentioned Edg ligand and serotonin ligand. Furthermore, preferably, the above-mentioned various preferred components are included. Further, one or more of the various additives described above may be included. As the additive of the present invention, one having a composition that gives the above-described medium of the present invention by dissolving in water or a basal medium is simple and preferable. In this case, the mixing ratio of various components contained in the additive is the same as the content ratio of each component in the medium. Examples of the basal medium include the various media described above that have been conventionally used for culturing mammalian cells.
- % Means “% by weight” unless otherwise specified, and the concentration of various additives means the final concentration in the medium.
- concentration of various additives means the final concentration in the medium.
- low serum medium C supplemented with 2.5 ng / mL basic fibroblast growth factor (bFGF) has a final concentration of bFGF in low serum medium C of 2.5 ng / mL. It means adding the amount.
- Example 1 Culture of human adipose tissue-derived stem cells (hMADS) (1-1) Production of ligand
- hMADS human adipose tissue-derived stem cells
- the change in the population doubling number (n) between 21 days from the start of the culture was calculated from the result of measuring the number of cells per cell passage using a hemocytometer.
- the population doubling number is the number (n) of cell divisions. In cell division, one cell divides into two. Therefore, when n divisions are performed, the number of cells is 2n .
- the population doubling number is obtained based on the following equation.
- Population doubling number (n) Log (2) [(P1 measured cell number / P1 seeded cell number) ⁇ (P2 measured cell number / P2 seeded cell number) ⁇ ...] (In the above formula, P1, P2,... Represent the first passage, the second passage,...)
- a large population doubling number indicates that the number of cells is twice as many, and a double number indicates that the number of cells is four times as large. indicating that the 2 x times more.
- FIG. 2 shows changes in the population doubling number when the concentration of S-1 is kept constant.
- conventional medium ⁇
- low serum medium C ⁇
- 0.1% S-1 ⁇
- 0.1% S-1 0.1% S-1
- 0.002% S-2 ⁇
- 0.1% S-1 0.02% S-2
- * 0.1% S-1, 0.2% S-2 (+)
- 0.1% S-1 0.5% S-
- the population doubling numbers of 2 ⁇ ), 0.1% S-1, 1% S-2 ( ⁇ ), and 0.1% S-1, 2% S-2 ( ⁇ ) are shown.
- FIG. 3 shows the results when 1% of S-3 is added to the low serum medium C described above.
- the population doubling numbers of conventional medium ( ⁇ ), low serum medium C ( ⁇ ), 1% S-1 ( ⁇ ), 1% S-2 ( ⁇ ) and 1% S-3 ( ⁇ ) are shown. Show.
- hMADS cultured in a medium obtained by adding S-3 to low serum medium C is stained to the same extent as cells cultured in a conventional medium containing 10% serum. It turns out that it differentiated into the bone cell. Therefore, it can be seen that all the cells cultured in these media have the ability to maintain undifferentiation, and there is no difference in the differentiation ability as stem cells. In addition, it was confirmed that even when human serum was used instead of FCS used in (1-2), the tendency of proliferation and differentiation shown in FIGS. 1 to 4 did not change.
- Example 2 Culture of human bone marrow-derived mesenchymal stem cells (hMSC) (2-1) Production of ligand As a serotonin ligand, 2.1 mg of serotonin hydrochloride (manufactured by Sigma) was added to 10 mL of DMEM (manufactured by LONZA). Upon dissolution, Ligand 1 (S-1) was produced.
- hMSC human bone marrow-derived mesenchymal stem cells
- LPA 1-oleyllysophosphatidic acid sodium salt
- S-2 ligand 2
- S1P sphingosine-1 -Phosphoric acid
- S-3 ligand 3
- a low serum medium obtained by adding S-1 and / or 2 prepared in (2-1) at various concentrations to the low serum medium C1 was obtained. Specifically, S-1 and / or S-2 were added at the following concentrations.
- Low serum medium (0.2% S-2) supplemented with 0% S-1 and 0.2% S-2 to low serum medium C1 A low serum medium (0.2% S-2, 0.001% S-1) obtained by adding 0.001% S-1 and 0.2% S-2 to the low serum medium C1;
- Low serum medium (0.2% S-2, 1% S-1) supplemented with 1% S-1 and 0.2% S-2 to low serum medium C1 A low serum medium (0.2% S-2, 1% S-1) supplemented with 1% S-1 and 0.2% S
- Low serum medium was obtained in which S-1 and / or 2 ′ prepared in (2-1) was added at various concentrations to low serum medium C2. Specifically, S-1 and / or S-2 ′ were added at the following concentrations. Low serum medium (0.1% S-2 ′, 1% S-1) obtained by adding 1% S-1 and 0.1% S-2 ′ to low serum medium C2, Low serum medium (0.02% S-2 ′, 1% S-1) obtained by adding 1% S-1 and 0.02% S-2 ′ to low serum medium C2, Low serum medium (0.01% S-2 ′, 1% S-1) obtained by adding 1% S-1 and 0.01% S-2 ′ to low serum medium C2, Low serum medium (0.002% S-2 ′, 1% S-1) obtained by adding 1% S-1 and 0.002% S-2 ′ to low serum medium C2, Low serum medium (0.0002% S-2 ′, 1% S-1) obtained by adding 1% S-1 and 0.0002% S-2 ′ to low serum medium C2.
- FIG. 5 shows changes in the population doubling number when the concentration of S-2 is kept constant.
- FIG. 6 shows the change in the population doubling number when the concentration of S-1 is kept constant.
- conventional medium ⁇
- low serum medium C1 ⁇
- 0.1% S-1 ⁇
- 0.1% S-1 0.002% S-2
- 0. 1% S-1 0.1% S-1
- 0.02% S-2 *
- 0.1% S-1, 2% S-2 ( ⁇ ) 1% S-1 ( ⁇ ), 1% S-2 ( ⁇ ) and 1% S-1, 1% S-2 ( ⁇ )
- FIG. 7 shows the results when 1% of S-3 was added to the low serum medium C1.
- conventional medium ( ⁇ ), low serum medium C1 ( ⁇ ), 1% S-1 ( ⁇ ), 1% S-2 ( ⁇ ) 1% S-3 ( ⁇ ) and 1% S-3 Indicates the population doubling number of 1% FCS ( ⁇ ).
- FIG. 8 shows changes in the population doubling number when the concentration of S-1 is kept constant.
- the conventional medium ( ⁇ ), 0.1% S-2 ′, 1% S-1 ( ⁇ ), 0.02% S-2 ′, 1% S-1 ( ⁇ ), 0.01% S-2 ', 1% S-1 ( ⁇ ), 0.002% S-2', 1% S-1 ( ⁇ ), 0.0002% S-2 ', 1% S-1 ( ⁇ ) Shows the population doubling number.
- Amino acids (all amino acids described above), inorganic salts (all inorganic salts described above), vitamins (all vitamins described above) and other additives (adenosine 5'-monophosphate, corticosterone, ethanolamine, 7 ⁇ 10 ⁇ 4 % in a medium containing D-galactose, D-glucose, insulin, reduced glutathione, lipoic acid, hypoxanthine, phenol red, progesterone, putrescine, pyruvate, thymidine, triiodothyronine and transferrin)
- Low-medium medium 3 (1% S) supplemented with 2-ME, 100 U / L penicillin streptomycin, 0.5% FCS, 2.5 ng / mLbFGF and 1% (1-1) S-3 -3 LS).
- serum-free medium 3 (1% S-3 SF) was obtained with the same composition as the above-mentioned low serum medium 3 except that FCS was not contained.
- the population doubling number (n) between 22 days from the start of the culture was calculated using the results of measuring the number of cells per cell passage using a hemocytometer. The results are shown in FIG. FIG. 10 shows the population doubling numbers of the conventional medium ( ⁇ ), 1% S-3 LS ( ⁇ ), and 1% S-3 SF ( ⁇ ).
- FCS1-4 conventional serum-containing medium
- the change in the population doubling number (n) during 18 days from the start of the culture was calculated using the results obtained by measuring the number of cells at each cell passage using a hemocytometer. Changes in the population doubling number when the FCS lot is changed are shown in FIGS. 11 to 14, the conventional medium (FCS1 to 4) is indicated by ( ⁇ ), and the low serum medium (1% S-3, 1% FCS (1 to 4)) is indicated by ( ⁇ ).
- the low serum medium (1% S-3, 1% FCS) has less effect on cell proliferation due to differences in FCS production lots than the conventional medium containing 10% serum.
- Example 5 Culture with human serum (culture of hMSC) (5-1) Production of Ligand 2.1 mg of serotonin hydrochloride and 2.3 mg of LPA were dissolved in 10 ml of PBS to produce Ligand 3 (S-3).
- the change in the population doubling number (n) during 18 days from the start of the culture was calculated using the results obtained by measuring the number of cells at each cell passage using a hemocytometer. Changes in the number of population doublings when the HS lot is changed are shown in FIGS.
- the conventional medium (HS1,2) is indicated by ( ⁇ )
- the low serum medium (1% S-3,1% HS (1,2)) is indicated by ( ⁇ ).
- Example 6 Culture 2 of human bone marrow-derived mesenchymal stem cells (hMSC) In water, amino acids (all amino acids described above), inorganic salts (all inorganic salts described above excluding copper sulfate, iron (III) nitrate, iron sulfate, magnesium chloride, disodium hydrogen phosphate, zinc sulfate), vitamins (All vitamins listed above) and other additives (adenosine 5'-monophosphate, corticosterone, ethanolamine, D-galactose, D-glucose, insulin, reduced glutathione, lipoic acid, phenol red, progesterone , Putrescine, pyruvate, triiodothyronine and transferrin) in a basic medium containing 1 ng / ml platelet-derived growth factor (PDGF), 2.5 ng / ml basic fibroblast growth factor (bFGF), 0.02 Wt% human serum albumin and 500 ⁇ M N-ace
- a conventional serum-containing medium was obtained by adding 100 U / mL penicillin / streptomycin and 10% FBS to DMEM (conventional medium A).
- the change in the population doubling number (n) for 18 days from the start of the culture was calculated using the results obtained by measuring the number of cells for each subculture using a hemocytometer.
- hMSCs Differentiation of hMSCs into adipocytes
- adipocyte differentiation medium DMEM, 10% FCS, 500 ⁇ M IBMX, Transfer to wells of a 48-well culture plate containing 0.3 mL of 1 ⁇ M dexamethasone, 1 ⁇ M insulin, 1 ⁇ M rosiglitazone
- DMEM fetal calf serum
- IBMX 500 ⁇ M IBMX
- hMSCs Differentiation of hMSCs into bone cells
- Cells maintained for several passages in conventional medium and serum-free growth medium A at a cell density of 3000 cells / cm 2 are treated with bone cell differentiation medium (DMEM, 10% FCS, 200 ⁇ M ascorbic acid, Transfer to wells of a 12-well culture plate containing 0.7 mL of 0.1 ⁇ M dexamethasone, 10 mM ⁇ -glycerophosphate), and induce differentiation into bone cells by culturing at 37 ° C. and 5% CO 2 for 21 days. It was. Differentiation into bone cells was confirmed by alizarin red S staining.
- DMEM 10% FCS, 200 ⁇ M ascorbic acid
- Example 7 Culture of human bone marrow-derived mesenchymal stem cells (hMSC) 3 In water, amino acids (all amino acids described above), inorganic salts (all inorganic salts described above excluding copper sulfate, iron (III) nitrate, iron sulfate, magnesium chloride, disodium hydrogen phosphate, zinc sulfate), vitamins (All vitamins listed above) and other additives (adenosine 5'-monophosphate, corticosterone, ethanolamine, D-galactose, D-glucose, insulin, reduced glutathione, lipoic acid, phenol red, progesterone , Putrescine, pyruvic acid, triiodothyronine and transferrin) in a basal medium, 0.02 wt% human serum albumin and 500 ⁇ M N-acetylcysteine (NAC), 100 U / ml penicillin streptomycin (GIBCO) , And serum-free growth
- the obtained serum-free growth medium B and 10 mL of each medium of the serum-free growth medium A and the conventional medium A prepared in Example 6 were placed in a culture dish with a diameter of 100 mm, respectively, and hMSC at an initial cell number of 20,000 cells / mL.
- the change in the population doubling number (n) for 21 days from the start of the culture was calculated using the results obtained by measuring the number of cells for each subculture using a hemocytometer.
- hMSCs Differentiation of hMSCs into adipocytes
- Cells maintained for several passages in conventional medium A or serum-free growth medium A or serum-free growth medium B at a cell density of 30000 cells / cm 2 are treated with adipocyte differentiation medium (DMEM, 10% FCS, 500 ⁇ M IBMX, 1 ⁇ M dexamethasone, 1 ⁇ M insulin, 1 ⁇ M rosiglitazone) transferred to wells of a 48-well culture plate containing 0.3 mL, and cultured for 14 days at 37 ° C., 5% CO 2. Differentiation induction was performed. Differentiation into adipocytes was confirmed by oil red O staining.
- FIG. 21 (A) cells subjected to differentiation induction after being subcultured and maintained in each of the three types of medium are stained to the same extent in the serum-free medium B of the present invention containing no growth factor. Even when differentiation was induced after maintaining the passage, differentiation was confirmed as in the conventional medium containing serum.
- hMSCs Differentiation of hMSCs into bone cells
- Cells maintained for several passages in conventional medium A or serum-free growth medium A or serum-free growth medium B at a cell density of 3000 cells / cm 2 are treated with bone cell differentiation medium (DMEM, 10%
- DMEM bone cell differentiation medium
- FCS 0.7 mL of FCS
- 0.1 ⁇ M dexamethasone 10 mM ⁇ -glycerophosphate
- the cells subjected to differentiation induction after being maintained for several passages in serum-free growth medium A or serum-free growth medium B are the same as those maintained for several passages in conventional medium A. It was stained to the extent that differentiation into bone cells was confirmed. It was revealed that the serum-free growth medium of the present invention maintains the ability to differentiate into bone cells even when it does not contain growth factors.
- FIG. 2 is a graph showing changes in the population doubling number of human adipose tissue-derived stem cells (hMADS) obtained in Example 1.
- FIG. 2 is a graph showing changes in the population doubling number of human adipose tissue-derived stem cells (hMADS) obtained in Example 1.
- FIG. 2 is a graph showing changes in the population doubling number of human adipose tissue-derived stem cells (hMADS) obtained in Example 1.
- FIG. The differentiation of human adipose tissue-derived stem cells (hMADS) into adipocytes (A) and differentiation into bone cells (B) are shown.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 2.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 2.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 2.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 2.
- the differentiation of human bone marrow-derived mesenchymal stem cells (hMSC) into fat cells (A) and differentiation into bone cells (B) are shown. It is a graph which shows the change of the population doubling number of the human fibroblast (hFB) obtained in Example 3.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 4.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 4.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 4.
- 6 is a graph showing changes in the population doubling number of human bone marrow-derived mesenchymal stem cells (hMSC) obtained in Example 4.
- FIG. It is a figure which shows the population doubling number of the human bone marrow origin mesenchymal stem cell (hMSC) culture
- FIG. It is a graph which shows the change of the population doubling number of the human bone marrow origin mesenchymal stem cell (hMSC) cultured in the culture medium containing human serum obtained in Example 5. It is a graph which shows the change of the population doubling number of the human bone marrow origin mesenchymal stem cell (hMSC) cultured in the culture medium containing human serum obtained in Example 5.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
R-O-CH2CH(OH)CH2PO4H2 (I)
(式中、Rは、炭素数10~30のアルキル基、炭素数10~30のアルケニル基又は炭素数10~30のアシル基である)
で表される化合物である。
(1-1)リガンドの製造
セロトニンリガンドとして、2.1mgのセロトニン塩酸塩(Sigma社製)を10mLのDMEM(LONZA社製)に溶解して、リガンド1(S-1)を製造した。 また、Edgリガンドとして、2.3mgの1-オレイルリゾホスファチジン酸ナトリウム塩(LPA:CAYMAN社製)を10mLのPBSに溶解して、リガンド2(S-2)を製造した。さらに、2.1mgのセロトニン塩酸塩及び2.3mgのLPAを10mLのPBSに溶解して、リガンド3(S-3)を製造した。
アミノ酸類(上記した全アミノ酸類)、無機塩類(上記した全無機塩類)、ビタミン類(上記した全ビタミン類)及び他の添加剤(アデノシン 5'-一りん酸、コルチコステロン、エタノールアミン、D-ガラクトース、D-グルコース、インスリン、還元型グルタチオン、リポ酸、ヒポキサンチン、フェノールレッド、プロゲステロン、プトレシン、ピルビン酸、チミジン、トリヨードチロニン及びトランスフェリン)を含む培地に、7×10-4%の2-メルカプトエタノール(2-Me)、100U/mLのペニシリン・ストレプトマイシン(GIBCO社製)、0.5%のウシ胎児血清(FCS)及び2.5ng/mLの塩基性繊維芽細胞増殖因子(bFGF)を加えた低血清培地Cを得た。
低血清培地Cに0%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2)、
低血清培地Cに0.001%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.001% S-1)、
低血清培地Cに0.01%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.01% S-1)、
低血清培地Cに0.1%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.1% S-1)、
低血清培地Cに1%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,1% S-1)、
低血清培地Cに10%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,10% S-1)、
低血清培地Cに0.1%のS-1及び0%のS-2を添加した低血清培地(0.1% S-1)、
低血清培地Cに0.1%のS-1及び0.002%のS-2を添加した低血清培地(0.1% S-1,0.002% S-2)、
低血清培地Cに0.1%のS-1及び0.02%のS-2を添加した低血清培地(0.1% S-1,0.02% S-2)、
低血清培地Cに0.1%のS-1及び0.2%のS-2を添加した低血清培地(0.1% S-1,0.2% S-2)、
低血清培地Cに0.1%のS-1及び0.5%のS-2を添加した低血清培地(0.1% S-1,0.5% S-2)、
低血清培地Cに0.1%のS-1及び1%のS-2を添加した低血清培地(0.1% S-1,1% S-2)、
低血清培地Cに0.1%のS-1及び2%のS-2を添加した低血清培地(0.1% S-1,2% S-2)、
低血清培地Cに1%のS-1及び0%のS-2を添加した低血清培地(1% S-1)、
低血清培地Cに0%のS-1及び1%のS-2を添加した低血清培地(1% S-2)、
低血清培地Cに1%のS-1及び1%のS-2を添加した低血清培地(1% S-1,1% S-2)。
なお、1%のS-1は約10μM、1%のS-2は約5μMに相当する。
集団倍化数(n)=Log(2)[(P1計測細胞数/P1播種細胞数)×(P2計測細胞数/P2播種細胞数)×・・・]
(上記の式中、P1、P2・・・は、第1継代、第2継代・・・を表す。)
図1は、S-2の濃度を一定にした場合の集団倍化数の変化を示す。
図1では、従来培地(○)、低血清培地C(▲)、0.2%S-2(×)、0.2% S-2,0.001% S-1(-)、0.2% S-2,0.01% S-1(*)、0.2% S-2,0.1% S-1(+)、0.2% S-2,1% S-1(△)、及び0.2% S-2,10% S-1(◆)の集団倍化数を示す。
図2では、従来培地(○)、低血清培地C(▲)、0.1%S-1(×)、0.1% S-1,0.002% S-2(-)、0.1% S-1,0.02% S-2(*)、0.1% S-1,0.2% S-2(+)、0.1% S-1,0.5% S-2(△)、0.1% S-1,1% S-2(◆)、及び0.1% S-1,2% S-2(◇)の集団倍化数を示す。
図3では、従来培地(○)、低血清培地C(▲)、1% S-1(◆)、1% S-2(■)及び1% S-3(●)の集団倍化数を示す。
(1-2)の従来培地及び低血清培地CにS-3を加えた培地を用いて数継代維持した細胞を、21000細胞/cm2の細胞密度で、脂肪細胞分化培地(DMEM、10%FCS、500μM イソブチルメチルキサンチン(IBMX)、1μMデキサメタゾン、1μMインスリン、1μMロシグリタゾン)0.1mLを含む96穴培養プレートのウェルに移し、37℃、5%CO2で10日間培養することにより、脂肪細胞への分化誘導を行った。脂肪細胞への分化は、オイルレッドO染色により確認した。結果を、図4(A)に示す。
(1-2)の従来培地及び低血清培地CにS-3を加えた培地を用いて数継代維持した細胞を、10000細胞/cm2の細胞密度で、骨細胞分化培地(DMEM、10%FCS、200μM アスコルビン酸、0.1μMデキサメタゾン、10mM β-グリセロホスフェート)0.5mLを含む24穴培養プレートのウェルに移し、37℃、5%CO2で15日間培養することにより、骨細胞への分化誘導を行った。骨細胞への分化は、アリザリンレッドS染色により確認した。結果を、図4(B)に示す。
また、(1-2)で用いたFCSの代わりにヒト血清を用いても、図1~4で示す増殖及び分化の傾向は変わらないことが確認された。
(2-1)リガンドの製造
セロトニンリガンドとして、2.1mgのセロトニン塩酸塩(Sigma社製)を10mLのDMEM(LONZA社製)に溶解して、リガンド1(S-1)を製造した。
また、Edgリガンドとして、2.3mgの1-オレイルリゾホスファチジン酸ナトリウム塩(LPA:CAYMAN社製)を10mLのPBSに溶解して、リガンド2(S-2)を、1.9mgのスフィンゴシン-1-リン酸(S1P:CAYMAN社製)を10mLのDMEMに溶解して、リガンド2(S-2’)を製造した。
さらに、2.1mgのセロトニン塩酸塩及び2.3mgのLPAを10mLのPBSに溶解して、リガンド3(S-3)を製造した。
実施例1で調製した基礎培地からヒポキサンチン及びチミジン並びに一部の無機塩類(硫酸銅、硝酸鉄(III)、硫酸鉄、塩化マグネシウム、リン酸水素二ナトリウム、硫酸亜鉛)を除外した基礎培地に、100U/mLのペニシリン・ストレプトマイシン(GIBCO社製)及び0.5%のFCSを加えた低血清培地C1を得た。また、前記基礎培地に、100U/mLのペニシリン・ストレプトマイシン(GIBCO社製)及び1.0%のFCSを加えた低血清培地C2を得た。
低血清培地C1に0%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2)、
低血清培地C1に0.001%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.001% S-1)、
低血清培地C1に0.01%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.01% S-1)、
低血清培地C1に0.1%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,0.1% S-1)、
低血清培地C1に1%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,1% S-1)、
低血清培地C1に10%のS-1及び0.2%のS-2を添加した低血清培地(0.2% S-2,10% S-1)、
低血清培地C1に0.1%のS-1及び0%のS-2を添加した低血清培地(0.1% S-1)、
低血清培地C1に0.1%のS-1及び0.002%のS-2を添加した低血清培地(0.1% S-1,0.002% S-2)、
低血清培地C1に0.1%のS-1及び0.02%のS-2を添加した低血清培地(0.1% S-1,0.02% S-2)、
低血清培地C1に0.1%のS-1及び0.2%のS-2を添加した低血清培地(0.1% S-1,0.2% S-2)、
低血清培地C1に0.1%のS-1及び1%のS-2を添加した低血清培地(0.1% S-1,1% S-2)、
低血清培地C1に0.1%のS-1及び2%のS-2を添加した低血清培地(0.1% S-1,2% S-2)、
低血清培地C1に1%のS-1及び0%のS-2を添加した低血清培地(1% S-1)、
低血清培地C1に0%のS-1及び1%のS-2を添加した低血清培地(1% S-2)、
低血清培地C1に1%のS-1及び1%のS-2を添加した低血清培地(1% S-1,1% S-2)、
低血清培地C1に0.5%のFCS、1%のS-1及び1%のS-2を添加した低血清培地(1% S-3,1% FCS)。
低血清培地C2に1%のS-1及び0.1%のS-2'を添加した低血清培地(0.1% S-2',1% S-1)、
低血清培地C2に1%のS-1及び0.02%のS-2'を添加した低血清培地(0.02% S-2',1% S-1)、
低血清培地C2に1%のS-1及び0.01%のS-2'を添加した低血清培地(0.01% S-2',1% S-1)、
低血清培地C2に1%のS-1及び0.002%のS-2'を添加した低血清培地(0.002% S-2',1% S-1)、
低血清培地C2に1%のS-1及び0.0002%のS-2'を添加した低血清培地(0.0002% S-2',1% S-1)。
図5は、S-2の濃度を一定にした場合の集団倍化数の変化を示す。
図5では、従来培地(○)、低血清培地C1(▲)、0.2%S-2(×)、0.2% S-2,0.001% S-1(-)、0.2% S-2,0.01% S-1(*)、0.2% S-2,0.1% S-1(+)、0.2% S-2,1% S-1(△)、0.2% S-2,10% S-1(◆)、1% S-1(□)、1% S-2(■)及び1% S-1,1% S -2(●)の集団倍化数を示す。
図6では、従来培地(○)、低血清培地C1(▲)、0.1%S-1(×)、0.1% S-1,0.002% S-2(-)、0.1% S-1,0.02% S-2(*)、0.1% S-1,0.2% S-2(+)、0.1% S-1,1% S-2(◆)、0.1% S-1,2% S-2(◇)、1% S-1(□)、1% S-2(■)及び1% S-1,1%S-2(●)の集団倍化数を示す。
図7では、従来培地(○)、低血清培地C1(▲)、1% S-1(◆)、1% S-2(■)1% S-3(●)及び1% S-3,1% FCS(◇)の集団倍化数を示す。
図8では、従来培地(○)、0.1% S-2’,1% S-1(△)、0.02% S-2’,1% S-1(◆)、0.01% S-2’,1% S-1(■)、0.002% S-2’,1% S-1(◇)、0.0002% S-2’,1% S-1(□)の集団倍化数を示す。
(2-2)の従来培地及び1% S-3,1% FCSを用いて数継代維持した細胞を、20000細胞/cm2の細胞密度で、脂肪細胞分化培地(DMEM、10%FCS、500μM イソブチルメチルキサンチン(IBMX)、1μMデキサメタゾン、1μMインスリン、1μMロシグリタゾン)0.1mLを含む96穴培養プレートのウェルに移し、37℃、5%CO2で14日間培養することにより、脂肪細胞への分化誘導を行った。脂肪細胞への分化は、オイルレッドO染色により確認した。結果を、図9(A)に示す。
(2-2)の従来培地及び1% S-3,1% FCSを用いて数継代維持した細胞を、3000細胞/cm2の細胞密度で、骨細胞分化培地(DMEM、10%FCS、200μM アスコルビン酸、0.1μMデキサメタゾン、10mM β-グリセロホスフェート)0.5mLを含む24穴培養プレートのウェルに移し、37℃、5%CO2で14日間培養することにより、骨細胞への分化誘導を行った。骨細胞への分化は、アリザリンレッドS染色により確認した。結果を、図9(B)に示す。
また、(2-2)で用いたFCSの代わりにヒト血清を用いても、図5~9で示す増殖及び分化の傾向は変わらないことが確認された。
さらに、Edgリガンドとして、LPAの代わりにS1Pを用いても、分化の傾向は変わらないことが確認された。
図10では、従来培地(○)、1% S-3 LS(●)及び1% S-3 SF(▲)の集団倍化数を示す。
(4-1)リガンドの製造
2.1mgのセロトニン塩酸塩及び2.3mgのLPAを10mlのPBSに溶解して、リガンド3(S-3)を製造した。
実施例1で調製した基礎培地からヒポキサンチン及びチミジン並びに一部の無機塩類(硫酸銅、硝酸鉄(III)、硫酸鉄、塩化マグネシウム、リン酸水素二ナトリウム、硫酸亜鉛)を除外した基礎培地に、100U/mlのペニシリン・ストレプトマイシン(GIBCO社製)、及びロットの異なるFCSを各々1.0%加えた低血清培地C2(FCS1~4)を得た。
(5-1)リガンドの製造
2.1mgのセロトニン塩酸塩及び2.3mgのLPAを10mlのPBSに溶解して、リガンド3(S-3)を製造した。
実施例1で調製した基礎培地からヒポキサンチン及びチミジン並びに一部の無機塩類(硫酸銅、硝酸鉄(III)、硫酸鉄、塩化マグネシウム、リン酸水素二ナトリウム、硫酸亜鉛)を除外した基礎培地に、100U/mlのペニシリン・ストレプトマイシン(GIBCO社製)、及びロットの異なるヒト血清HSを各々1.0%加えた低血清培地C3(HS1,2)を得た。
水中に、アミノ酸類(上記した全アミノ酸類)、無機塩類(硫酸銅、硝酸鉄(III)、硫酸鉄、塩化マグネシウム、リン酸水素二ナトリウム、硫酸亜鉛を除外した上記した全無機塩類)、ビタミン類(上記した全ビタミン類)及び他の添加剤(アデノシン 5'-一りん酸、コルチコステロン、エタノールアミン、D-ガラクトース、D-グルコース、インスリン、還元型グルタチオン、リポ酸、フェノールレッド、プロゲステロン、プトレシン、ピルビン酸、トリヨードチロニン及びトランスフェリン)を含む基礎培地に1ng/mlの血小板由来増殖因子(PDGF)、2.5ng/mlの塩基性繊維芽細胞増殖因子(bFGF)、0.02重量%のヒト血清アルブミンおよび500μMのN-アセチルシステイン(NAC)、100U/mlのペニシリン・ストレプトマイシン(GIBCO社製)、及び1%の(1-1)で製造したS-3を加えた無血清増殖培地Aを得た。
従来培地A及び無血清増殖培地Aで数継代維持した細胞を、30000細胞/cm2の細胞密度で、脂肪細胞分化培地(DMEM、10%FCS、500μMのIBMX、1μMのデキサメタゾン、1μMのインスリン、1μMのロシグリタゾン)0.3mLを含む48穴培養プレートのウェルに移し、37℃、5%CO2で14日間培養することにより、脂肪細胞への分化誘導を行った。脂肪細胞への分化は、オイルレッドO染色により確認した。
従来培地及び無血清増殖培地Aで数継代維持した細胞を、3000細胞/cm2の細胞密度で、骨細胞分化培地(DMEM、10%FCS、200μMのアスコルビン酸、0.1μMのデキサメタゾン、10mMのβ-グリセロホスフェート)0.7mLを含む12穴培養プレートのウェルに移し、37℃、5%CO2で21日間培養することにより、骨細胞への分化誘導を行った。骨細胞への分化は、アリザリンレッドS染色により確認した。
水中に、アミノ酸類(上記した全アミノ酸類)、無機塩類(硫酸銅、硝酸鉄(III)、硫酸鉄、塩化マグネシウム、リン酸水素二ナトリウム、硫酸亜鉛を除外した上記した全無機塩類)、ビタミン類(上記した全ビタミン類)及び他の添加剤(アデノシン 5'-一りん酸、コルチコステロン、エタノールアミン、D-ガラクトース、D-グルコース、インスリン、還元型グルタチオン、リポ酸、フェノールレッド、プロゲステロン、プトレシン、ピルビン酸、トリヨードチロニン及びトランスフェリン)を含む基礎培地に0.02重量%のヒト血清アルブミンおよび500μMのN-アセチルシステイン(NAC)、100U/mlのペニシリン・ストレプトマイシン(GIBCO社製)、及び1%の(1-1)で製造したS-3を加えた無血清増殖培地Bを得た。
従来培地A又は無血清増殖培地A若しくは無血清増殖培地Bで数継代維持した細胞を、30000細胞/cm2の細胞密度で、脂肪細胞分化培地(DMEM、10%FCS、500μMのIBMX、1μMのデキサメタゾン、1μMのインスリン、1μMのロシグリタゾン)0.3mLを含む48穴培養プレートのウェルに移し、37℃、5%CO2で14日間培養することにより、脂肪細胞への分化誘導を行った。脂肪細胞への分化は、オイルレッドO染色により確認した。
従来培地A又は無血清増殖培地A若しくは無血清増殖培地Bで数継代維持した細胞を、3000細胞/cm2の細胞密度で、骨細胞分化培地(DMEM、10%FCS、200μMのアスコルビン酸、0.1μMのデキサメタゾン、10mMのβ-グリセロホスフェート)0.7mLを含む12穴培養プレートのウェルに移し、37℃、5%CO2で21日間培養することにより、骨細胞への分化誘導を行った。骨細胞への分化は、アリザリンレッドS染色により確認した。
Claims (23)
- 内皮細胞分化遺伝子(Edg)ファミリーレセプターに対するリガンドと、セロトニンレセプターに対するリガンドとを含む、哺乳動物体細胞用培地。
- 無血清又は低血清培地である請求項1記載の培地。
- 内皮細胞分化遺伝子ファミリーレセプターに対する前記リガンドの培地中の濃度が0.01~100μM、セロトニンレセプターに対する前記リガンドの培地中の濃度が0.1~100μMである請求項1又は2記載の培地。
- 内皮細胞分化遺伝子ファミリーレセプターに対する前記リガンドが、リゾホスファチジン酸(LPA)及びその塩、スフィンゴシン1リン酸(S1P)並びに内皮細胞分化遺伝子(Edg)ファミリーレセプターのアゴニストから成る群より選択される少なくとも1種である請求項1ないし3のいずれか1項に記載の培地。
- 内皮細胞分化遺伝子ファミリーレセプターに対する前記リガンドが、リゾホスファチジン酸(LPA)及びその塩から成る群より選択される少なくとも1種であり、その培地中の濃度が0.25~10μM、セロトニンレセプターに対する前記リガンドの培地中の濃度が0.25~20μMである請求項1又は2記載の培地。
- セロトニンレセプターに対する前記リガンドが、セロトニン、その塩及びセロトニンレセプターのアゴニストから成る群より選択される少なくとも1種である請求項1ないし5のいずれか1項に記載の培地。
- 抗酸化剤をさらに含む請求項1ないし6のいずれか1項に記載の培地。
- 前記抗酸化剤が、N-アセチルシステイン及びL-システインから成る群より選ばれる少なくとも1種である請求項7記載の培地。
- 前記抗酸化剤の培地中の濃度が0.01mM~10mMである請求項7又は8記載の培地。
- 動物血清アルブミンをさらに含む請求項1ないし9のいずれか1項に記載の培地。
- 前記血清アルブミンの培地中の濃度が0.0001~10重量%である請求項1ないし10のいずれか1項に記載の培地。
- 成長因子をさらに含む請求項1ないし11のいずれか1項に記載の培地。
- 前記成長因子が、血小板由来成長因子(PDGF)、塩基性繊維芽細胞成長因子(bFGF)及び上皮成長因子(EGF)からなる群より選択される少なくとも1種である請求項12記載の培地。
- 培地中に含まれる前記成長因子が、血小板由来成長因子(PDGF)及び塩基性繊維芽細胞成長因子(bFGF)の2種類である請求項13記載の培地。
- 前記成長因子の培地中の濃度が0.1~100ng/mLである請求項12ないし14のいずれか1項に記載の培地。
- 内皮細胞分化遺伝子(Edg)ファミリーレセプターに対するリガンドと、セロトニンレセプターに対するリガンドとを含む、哺乳動物体細胞用培地の添加剤。
- 内皮細胞分化遺伝子ファミリーレセプターに対する前記リガンドが、リゾホスファチジン酸(LPA)及びその塩、スフィンゴシン1リン酸(S1P)並びに内皮細胞分化遺伝子(Edg)ファミリーレセプターのアゴニストから成る群より選択される少なくとも1種である請求項16記載の添加剤。
- セロトニンレセプターに対する前記リガンドが、セロトニン、その塩及びセロトニンレセプターのアゴニストから成る群より選択される少なくとも1種である請求項16又は17記載の添加剤。
- 抗酸化剤をさらに含む請求項16ないし18のいずれか1項に記載の添加剤。
- 動物血清アルブミンをさらに含む請求項16ないし19のいずれか1項に記載の添加剤。
- 成長因子をさらに含む請求項16ないし20のいずれか1項に記載の添加剤。
- 水又は基礎培地に溶解することにより請求項1ないし15のいずれか1項に記載の培地を与える組成を有する請求項16ないし21のいずれか1項に記載の添加剤。
- 請求項1ないし15のいずれか1項に記載の培地中で、哺乳動物体細胞を培養することを含む、哺乳動物体細胞の培養方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/810,729 US20110008893A1 (en) | 2007-12-28 | 2008-12-26 | Medium for mammalian somatic cells and additive therefor |
EP08868742.1A EP2233565B1 (en) | 2007-12-28 | 2008-12-26 | Medium for mammalian somatic cells and additive therefor |
JP2009548105A JPWO2009084662A1 (ja) | 2007-12-28 | 2008-12-26 | 哺乳動物体細胞用培地及びそのための添加剤 |
CN2008801239879A CN101918542B (zh) | 2007-12-28 | 2008-12-26 | 哺乳动物体细胞用培养基以及该培养基的添加剂 |
US13/523,581 US9410125B2 (en) | 2007-12-28 | 2012-06-14 | Medium for mammalian somatic cells and additive therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007340802 | 2007-12-28 | ||
JP2007-340802 | 2007-12-28 | ||
JP2008-151295 | 2008-06-10 | ||
JP2008151295 | 2008-06-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/523,581 Division US9410125B2 (en) | 2007-12-28 | 2012-06-14 | Medium for mammalian somatic cells and additive therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009084662A1 true WO2009084662A1 (ja) | 2009-07-09 |
Family
ID=40824375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/073806 WO2009084662A1 (ja) | 2007-12-28 | 2008-12-26 | 哺乳動物体細胞用培地及びそのための添加剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20110008893A1 (ja) |
EP (1) | EP2233565B1 (ja) |
JP (1) | JPWO2009084662A1 (ja) |
KR (1) | KR101574989B1 (ja) |
CN (1) | CN101918542B (ja) |
WO (1) | WO2009084662A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010095684A1 (ja) * | 2009-02-23 | 2010-08-26 | 富士レビオ株式会社 | 脂肪細胞への分化誘導培地及び方法 |
JP2012157263A (ja) * | 2011-01-31 | 2012-08-23 | Seems Inc | アルツハイマー病治療に向けたヒト脂肪組織由来間葉系幹細胞 |
JP2013208104A (ja) * | 2012-03-02 | 2013-10-10 | Yamaguchi Univ | 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法 |
JP2014097055A (ja) * | 2012-11-13 | 2014-05-29 | Grifols Sa | ヒト間葉系幹細胞のための培養培地 |
EP2496199B1 (en) | 2009-11-06 | 2016-08-03 | Unicharm Corporation | Disposable wearing article |
WO2020116623A1 (ja) | 2018-12-07 | 2020-06-11 | 関東化学株式会社 | 多能性幹細胞用未分化維持培地 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5663841B2 (ja) * | 2009-02-23 | 2015-02-04 | 富士レビオ株式会社 | 骨細胞への分化誘導培地及び方法 |
US20120207790A1 (en) * | 2009-10-08 | 2012-08-16 | National University Corporation Nagoya University | Immunosuppressing agent comprising mesenchymal stem cell derived from adipose tissue, and use thereof |
WO2013071459A2 (es) * | 2011-10-24 | 2013-05-23 | Universidad Del Desarrollo | Composición que comprende un glucocorticoide y una tiazolinediona para inducir diferenciación adipogénica completa de células madre de mamíferos |
US9868935B2 (en) * | 2012-04-24 | 2018-01-16 | Crioestaminal, Saúde E Tecnologia, Sa. | Composition and method of stem cells for preservation of cardiac tissue |
GB201421092D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
CN104480066B (zh) * | 2014-12-30 | 2018-03-30 | 陕西瑞盛生物科技有限公司 | 一种软骨细胞培养基及软骨细胞培养方法 |
JP6754279B2 (ja) * | 2016-11-25 | 2020-09-09 | 株式会社日立プラントサービス | 細胞培養培地、並びにこれを用いた細胞培養装置及び細胞培養方法 |
CN106434532A (zh) * | 2016-12-22 | 2017-02-22 | 叶宗耀 | 一种培养肝细胞的培养基及其制备方法 |
CN107345216B (zh) * | 2017-07-28 | 2020-11-06 | 暨南大学 | 一种脂肪干细胞培养基及其应用 |
CN111004778A (zh) * | 2019-12-16 | 2020-04-14 | 江苏艾洛特生物科技有限公司 | 一种细胞无血清培养基添加物、培养基及用途 |
CN114591897B (zh) * | 2020-12-03 | 2024-02-23 | 梦芊科技知识产权有限公司 | 使用无异源培养基三维培养间充质干细胞的方法 |
CN114107188A (zh) * | 2021-11-30 | 2022-03-01 | 滨州医学院 | 一种干细胞成膜培养基及其应用 |
CN116254223A (zh) * | 2023-01-12 | 2023-06-13 | 青岛农业大学 | 用于冻存后猪皮肤干细胞复苏的培养基及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039487A1 (en) * | 1995-06-05 | 1996-12-12 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
WO2003104442A1 (en) * | 2002-06-07 | 2003-12-18 | Es Cell International Pte Ltd | Methods of regulating differentiation in stem cells |
WO2004039965A1 (ja) * | 2002-10-31 | 2004-05-13 | Riken | 多能性幹細胞培養用の組成物とその使用 |
WO2006029197A1 (en) * | 2004-09-08 | 2006-03-16 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
WO2007080919A1 (ja) | 2006-01-13 | 2007-07-19 | Japan Science And Technology Agency | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169610B2 (en) * | 2002-01-25 | 2007-01-30 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
-
2008
- 2008-12-26 US US12/810,729 patent/US20110008893A1/en not_active Abandoned
- 2008-12-26 JP JP2009548105A patent/JPWO2009084662A1/ja active Pending
- 2008-12-26 CN CN2008801239879A patent/CN101918542B/zh not_active Expired - Fee Related
- 2008-12-26 WO PCT/JP2008/073806 patent/WO2009084662A1/ja active Application Filing
- 2008-12-26 EP EP08868742.1A patent/EP2233565B1/en not_active Not-in-force
- 2008-12-26 KR KR1020107005263A patent/KR101574989B1/ko not_active IP Right Cessation
-
2012
- 2012-06-14 US US13/523,581 patent/US9410125B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039487A1 (en) * | 1995-06-05 | 1996-12-12 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
JPH11506610A (ja) | 1995-06-05 | 1999-06-15 | オシリス セラピューティクス,インコーポレイテッド | ヒト間葉幹細胞用合成培地 |
WO2003104442A1 (en) * | 2002-06-07 | 2003-12-18 | Es Cell International Pte Ltd | Methods of regulating differentiation in stem cells |
JP2006505248A (ja) | 2002-06-07 | 2006-02-16 | イーエス・セル・インターナショナル・プライヴェート・リミテッド | 幹細胞における分化を制御する方法 |
WO2004039965A1 (ja) * | 2002-10-31 | 2004-05-13 | Riken | 多能性幹細胞培養用の組成物とその使用 |
WO2006029197A1 (en) * | 2004-09-08 | 2006-03-16 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
WO2007080919A1 (ja) | 2006-01-13 | 2007-07-19 | Japan Science And Technology Agency | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
Non-Patent Citations (18)
Title |
---|
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 34, 2006, pages 274 - 285 |
DING V ET AL.: "Deciphering the importance of three key media components in human embryonic stem cell cultures.", BIOTECHNOL. LETT., vol. 28, 2006, pages 491 - 495, XP019231244 * |
FOLIA HISTOCHEMICA ET CYTOBIOLOGICAL, vol. 44, no. 4, 2006, pages 215 - 230 |
HAHN A ET AL.: "Induction of connective tissue growth factor by activation of heptahelical receptors.", J. BIOL. CHEM., vol. 275, 2000, pages 37429 - 37435, XP008138427 * |
IMAMURA F ET AL.: "Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D.", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 193, 1993, pages 497 - 503, XP024767522 * |
J BIOL CHEM., vol. 277, no. 29, 2002, pages 25851 - 25854 |
J CELL BIOCHEM., vol. 64, no. 2, 1997, pages 278 - 94 |
J LEUKOC BIOL., vol. 76, no. 1, 2004, pages 152 - 61 |
J. BIOL. CHEM., vol. 280, no. 15, 2005, pages 14656 - 14662 |
LU J ET AL.: "Defined culture conditions of human embryonic stem cells.", PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 5688 - 5693, XP008090827 * |
MOLECULAR HUMAN REPRODUCTION, vol. 8, no. 3.3, 2002, pages 228 - 236 |
RAJALA K ET AL.: "Testing of nine different xeno- free culture media for human embryonic stem cell cultures.", HUMAN REPROD., vol. 22, May 2007 (2007-05-01), pages 1231 - 1238, XP008125320 * |
SAKAI K ET AL.: "Effects of phospholipids on growth of Chinese hamster ovary cells in serum- free media.", J. BIOSCI. BIOENG., vol. 88, 1999, pages 306 - 309, XP008138429 * |
SCI. STKE, vol. 2005, no. 292, 12 July 2005 (2005-07-12), pages 35 |
SCI. STKE, vol. 2005, no. 292, 12 July 2005 (2005-07-12), pages E35 |
SCIENCE, vol. 294, 2001, pages 1875 - 1878 |
See also references of EP2233565A4 * |
ZHOU F-Q ET AL.: "Growth cone collapse through coincident loss of actin bundles and leading edge actin without actin depolymerization.", J. CELL BIOL., vol. 153, 2001, pages 1071 - 1083, XP008138425 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010095684A1 (ja) * | 2009-02-23 | 2010-08-26 | 富士レビオ株式会社 | 脂肪細胞への分化誘導培地及び方法 |
EP2496199B1 (en) | 2009-11-06 | 2016-08-03 | Unicharm Corporation | Disposable wearing article |
JP2012157263A (ja) * | 2011-01-31 | 2012-08-23 | Seems Inc | アルツハイマー病治療に向けたヒト脂肪組織由来間葉系幹細胞 |
JP2013208104A (ja) * | 2012-03-02 | 2013-10-10 | Yamaguchi Univ | 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法 |
JP2014097055A (ja) * | 2012-11-13 | 2014-05-29 | Grifols Sa | ヒト間葉系幹細胞のための培養培地 |
WO2020116623A1 (ja) | 2018-12-07 | 2020-06-11 | 関東化学株式会社 | 多能性幹細胞用未分化維持培地 |
Also Published As
Publication number | Publication date |
---|---|
CN101918542A (zh) | 2010-12-15 |
KR101574989B1 (ko) | 2015-12-21 |
CN101918542B (zh) | 2013-06-12 |
JPWO2009084662A1 (ja) | 2011-05-19 |
KR20100097649A (ko) | 2010-09-03 |
US9410125B2 (en) | 2016-08-09 |
US20120329155A1 (en) | 2012-12-27 |
EP2233565A4 (en) | 2011-12-07 |
US20110008893A1 (en) | 2011-01-13 |
EP2233565B1 (en) | 2015-05-13 |
EP2233565A1 (en) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009084662A1 (ja) | 哺乳動物体細胞用培地及びそのための添加剤 | |
WO2018164228A1 (ja) | Ror1陽性の間葉系幹細胞を含有する、線維症を伴う疾患の予防又は処置のための医薬組成物、及びその調製方法、並びにror1陽性の間葉系幹細胞を用いる線維症を伴う疾患の予防又は処置方法 | |
US10184112B2 (en) | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof | |
WO2016136986A1 (ja) | 間葉系幹細胞培養用培地、間葉系幹細胞の培養方法及び間葉系幹細胞 | |
JP5515319B2 (ja) | 脂肪細胞への分化誘導培地及び方法 | |
WO2017038784A1 (ja) | Ror1陽性の間葉系幹細胞及びその調製方法、ror1陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにror1陽性の間葉系幹細胞を用いる疾患の予防又は治療方法 | |
JP2014525262A (ja) | 間葉系幹細胞の基本培養培地の調製方法、間葉系幹細胞の基本培養培地及びこれを利用して培養分化した細胞治療剤 | |
WO2016159177A1 (ja) | キレート化鉄を含む神経幹細胞用培地 | |
JP7173007B2 (ja) | リボフラビン誘導体含有培地 | |
US9315777B2 (en) | Culture medium and method for inducing differentiation into bone cells | |
JPWO2017170925A1 (ja) | Egfr及びmic−abからなる群より選択される少なくとも1種の細胞表面マーカーを高発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法 | |
JP2020129970A (ja) | 多能性幹細胞を培養するための組成物及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880123987.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08868742 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20107005263 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009548105 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008868742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12810729 Country of ref document: US |